Dyne Therapeutics, Inc. (DYN)
After hours:
| Previous close | 42.70 |
| Open | 43.36 |
| Bid | 44.50 x 200 |
| Ask | 44.63 x 200 |
| Day's range | 42.84 - 44.88 |
| 52-week range | 6.40 - 45.46 |
| Volume | |
| Avg. volume | 1,254,195 |
| Market cap | 4.429B |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.98 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 46.67 |
ZacksWhat Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
Does Dyne Therapeutics, Inc. (DYN) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksDyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
Dyne Therapeutics (DYN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
GlobeNewswireDyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New D
